Eugene Braunwald.

Safety End Points The main safety end point of moderate or heavy bleeding occurred in 438 patients in the vorapaxar group, as compared with 267 patients in the placebo group . There was no proof heterogeneity in the effect ofContinue reading… Eugene Braunwald.